1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Microbiome-Targeted Therapeutics in Immunology

Microbiome-Targeted Therapeutics in Immunology

  • March 2018
  • 78 pages
  • ID: 5385691
  • Format: PDF
  • GlobalData

Summary

Table of Contents

Search Inside

Microbiome-Targeted Therapeutics in Immunology

Summary
Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. This report focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis and on the development of therapies targeting the gut microbiome for the treatment of Crohn’s disease, ulcerative colitis, and irritable bowel syndrome.

There are 10 pipeline therapies in clinical development (Phase I through Phase IIb/III) targeting the gut microbiome for the treatment of Crohn’s disease, UC, and IBS, while there are only three pipeline therapies in clinical development (Phase I through Phase III) targeting the skin microbiome for the treatment of acne, AD, and PsO.Currently, there are only three late-stage pipeline therapies targeting the microbiome in immunology - AOBiome’s Phase III B-244 for the treatment of acne, Synthetic Biologics’ Phase IIb/III SYN-010 (lovastatin MR) for the treatment of IBS-C, and Qu Biologics Phase IIB QBECO-SSI for Crohn’s disease.

Qu Biologics and AOBiome are the only two companies with microbiome-targeted therapeutics in both early- and late-stage development, but they are both banking on the success of the same drug, marking a substantial risk for these companies. Qu Biologics’ QBECO-SSI is in Phase IIb development for Crohn’s disease and Phase IIa development for UC, while AOBiome’s B-244 is in Phase III development for acne and Phase II development for AD.

The report "Microbiome-Targeted Therapeutics in Immunology", combines key opinion leader and payer insight with in-house analyst expertise to provide an insight-rich look at the microbiome space in immunology.

Components of the report include -
- Overview of the Gut and Skin Microbiome - microbial dysbiosis by indication
- Epidemiology Overview - prevalent or diagnosed prevalent cases by indication for the 16MM
- Pipeline Assessment-promising late-stage products and early-stage pipeline by indication
- Key Players - leading industry companies by indication
- Clinical Trials Mapping and Design - trial breakdown by phase/indication and trial design by indication
- Fecal Microbiota Transplants-opportunities and challenges for gastrointestinal indications
- Pricing, Reimbursement and Regulatory Strategy - US payer perspective on late-stage therapies
- Market Outlook - market potential estimation of late-stage therapies and key launch dates

Companies mentioned in this report: Qu Biologics, Synthetic Biologics, 4D Pharma, Enterome Bioscience, Second Genome, Seres Therapeutics, Rebiotix, Intrexon, Vedanta Biosciences, AOBiome, Matrisys Bioscience and SFA Therapeutics

Scope
This report combines key opinion leader and payer insight with in-house analyst expertise to provide an insight-rich look at the microbiome space in immunology.

Components of the report include -
- Overview of the Gut and Skin Microbiome: microbial dysbiosis by indication
- Epidemiology Overview: prevalent or diagnosed prevalent cases by indication for the 16MM
- Pipeline Assessment: promising late-stage products and early-stage pipeline by indication
- Key Players: leading industry companies by indication
- Clinical Trials Mapping and Design: trial breakdown by phase/indication and trial design by inidcation
- Fecal Microbiota Transplants: opportunities and challenges for gastrointestinal indications
- Pricing, Reimbursement and Regulatory Stategy: US payer perspective on late-stage therapies
- Market Outlook: market potential estimation of late-stage therapies and key launch dates

Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global microbiome market in immunology.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Gain insights to help plan and design your clinical trials.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Identify key pricing and reimbursement strategies.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Anti Peptic Ulcer Drugs Markets in China

  • $ 4000
  • January 2021
  • 211 pages

China’s demand for Anti Peptic Ulcer Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...

  • China
  • Digestive System Disorder
  • Industry analysis
  • Prescription Drug Sales
  • Industrial Production

ref:plp2018

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on